Estudo da síndrome da ceratoconjuntivite seca de pacientes soropositivos para o vírus da imunodeficiência adquirida humana tipo 1 e com síndrome da imunodeficiência adquirida, em uso ou não de terapia anti-retroviral combinada (HAART)

Rodrigues, Márcia Lopes; Rodrigues, Maria de Lourdes Veronesi; Freitas, João Alberto Holanda de

doi:10.1590/s0004-27492004000200018

Cited by 4 publications

(6 citation statements)

References 13 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In HAART era, the number of infections/inflammations decreased and the most prevalent ocular problem was keratoconjunctivitis sicca, supporting the results of a study carried out in the same region [28].…”

Section: Discussionsupporting

confidence: 70%

Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era

Rodrigues

Figueiredo

et al. 2007

Braz J Infect Dis

Self Cite

View full text Add to dashboard Cite

This study determined the total frequency of patients with AIDS and ophthalmologic problems before and after the introduction of combined highly active antiretroviral therapy (HAART), regardless of the use of this treatment; it also determined the frequency of external ocular diseases, intraocular infections and inflammations, and problems of the anterior portion of the optic nerve in these two groups of patients; and it determined the differences in the frequency of ophthalmologic problems in patients receiving HAART or not. This was a retrospective study of 207 patients examined using the same protocol, from June 1995 to February 1998 (n=58, pre-HAART era) and from March 1998 to May 2005 (n=149, HAART era). The frequency of ophthalmologic problems was significantly higher in the pre-HAART group, with a predominance of intraocular infections and inflammations. Comparison of patients receiving HAART or not revealed that ocular involvement tended to be reduced in the treated group and that treatment was effective in preventing infectious diseases; however, the prevalence of external ocular diseases was similar in the patients receiving HAART or not. As a consequence of HAART, we observed a reduction in the frequency of ocular problems, especially intraocular infections and inflammations. However, this benefic influence was less important in the ocular surface or in external ocular disease.

show abstract

Section: Discussionsupporting

confidence: 70%

Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era

Rodrigues

Figueiredo

et al. 2007

Braz J Infect Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…al. observed a significant increase in the frequency of the dry eye syndrome in patients with the disease developed for over four years, especially among those who were on HAART, but the decrease in tear production was not related to the severity or time of infection (25) . In the group studied, all patients were using HAART, and the time of infection was not taken into account; however, we did not consider the relevant fact due to not observing differences between them and the controls.…”

Section: Discussionmentioning

confidence: 86%

Evaluation of tear film function, ocular surface and tear film in HIV-seropositive patients

Mosena¹,

Pinheiro²,

Alhadeff³

et al. 2015

Revista Brasileira De Oftalmologia

View full text Add to dashboard Cite

RESUMOObjective: Evaluate tear function, tear film and ocular surface in patients with positive serology for HIV. Methods: Observational, cross-sectional, quantitative and analytical study, performed between june and october 2011, in the HSPE-FMO, SP, Ophthalmology Department, including 32 patients. Sixteen were HIV-positive patients and 16 HIV-negative. Results: There was no significant statistical difference in the middle age between both groups (p=0.083). The ferning test was statistically different in HIV group (with predominance of III and IV) compared to the control group (in which predominated the patterns I and II), both in the right and the left eye (p = 0.019 and p=0.001, respectively). Other parameters were not statistically significant between the groups. Conclusion: HIV-positive patients had no changes in lacrimal function and ocular surface, however, samples of tears showed differences considered statistically significant in the crystallization test, compared with samples obtained from controls.

show abstract

“…Foram descritas prevalências iguais a 21% (24) e 38.8% (21) em homens e 16.9% (23) em mulheres. Rodrigues et al (30) relataram prevalência igual a 25,8%, sem diferença em relação ao sexo. Na população geral, o sexo feminino é considerado um fator de risco consistente para desenvolvimento de olho seco (3,28) .…”

Section: Discussionunclassified

“…Rodrigues e cols. (30) observaram um aumento significativo da freqüência da síndrome de olho seco nos pacientes com doença acima de quatro anos, principalmente entre os que estavam em uso de terapia antirretroviral oral. No presente estudo, os pacientes apresentaram a doença controlada em uso de terapia HAART e os grupos eram homogêneos em relação às condições clínicas.…”

Section: Discussionunclassified

See 1 more Smart Citation

Uso de ciclosporina 0,05% tópica no tratamento do olho seco de pacientes portadores do vírus HIV

Barreto¹,

Biancardi²,

Nascimento³

et al. 2009

Rev. bras.oftalmol.

View full text Add to dashboard Cite

Estudo da síndrome da ceratoconjuntivite seca de pacientes soropositivos para o vírus da imunodeficiência adquirida humana tipo 1 e com síndrome da imunodeficiência adquirida, em uso ou não de terapia anti-retroviral combinada (HAART)

Cited by 4 publications

References 13 publications

Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era

Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era

Evaluation of tear film function, ocular surface and tear film in HIV-seropositive patients

Uso de ciclosporina 0,05% tópica no tratamento do olho seco de pacientes portadores do vírus HIV

Contact Info

Product

Resources

About